Roche Holding Ltd · SIX:RO
Roche — Bernstein's 23rd Annual Pan European Premium Review Conference 2024
26 slides from Roche's conference presentation, Nov 27, 2024
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Opening remarks
Opening remarks Alan Hippe | CFO Roche Group Bernstein’s Premium Review Conference 27 November 2024
Slide 4: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 5: YTD Sep 2024: Strong growth in both divisions
YTD Sep 2024: Strong growth in both divisions Q3 without significant COVID-19 impact Pharma* Diagnostics* Quarterly sales evolution 2022-2024 Quarterly sales evolution 2022-2024 % CER % CER 30% 30% +24% 20% 20% +12% +9% +10% +10% +9% +9% +7% +7% +7% +7% +8% +8% +7% +8% +8% +9% +7% 10% +6% +4% 10% +4
Slide 6: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio Significant milestones achieved in Q3 to enable future growth +5% YTD Sep 2024 sales Diagnostics: +8% base business growth (CHFbn, YoY CER growth) (+8%)* Significant launches upcoming Itovebi: US approval in 1L PIK3CA-mut HR+ BC 10.7 Tecentriq Hybreza: US ap
Slide 7: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term 2024 NME update: US approval for Itovebi (inavolisib) in HR+ breast cancer and PiaSky in PNH achieved CHFm % of Pharma Sales2 20.0 56% 18.0 50% 16.0 42% 14.0 12.0 34% 10.0 8.0 1 6.0 4.0 2.0 0.0 YTD Sep 2021 YTD Sep 2022 YTD Sep 2023 YTD Sep 20
Slide 8: A solid base to deliver future growth
A solid base to deliver future growth Pipeline and business development to add significant upside potential illustrative Business development • BD to accelerate pipeline portfolio • In-house pipeline with upside Pharma pipeline potential • On-market Pharma portfolio to deliver growth until 2027 Sale
Slide 9: 2024 guidance raised at HY
2024 guidance raised at HY Core EPS guidance raised from “broadly in line with sales” to “high single digit Core EPS growth” Group sales growth1 Mid single digit sales growth High single digit Core EPS growth Core EPS growth1 excl. impact from resolution of tax disputes in 2023 Dividend outlook Furt
Slide 10: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 11: Our new Pharma Strategy
Our new Pharma Strategy Providing clarity and intentional focus to leverage our scientific strengths and impact patients globally Where we play: Priority Therapeutic Areas How we succeed: Core capabilities Neurology Oncology/ Hematology Modalities & Devices Manufacturing Technologies Ophthalmology I
Slide 12: Global burden of disease by Therapeutic Area
Global burden of disease by Therapeutic Area Our focus therapeutic areas address ~60% of the global burden of disease and millions of patients worldwide Global Burden of Disease in 2023 and 2035 Growth, Number of people living with diseases in our (million DALYs) p.p % committed therapeutic areas gl
Slide 13: Selecting our therapeutic areas and focus disease areas
Selecting our therapeutic areas and focus disease areas Our focus considers societal burden and transformational potential, as well as Roche’s current capabilities External drivers Internal drivers Burden of disease and Potential to yield Roche’s strengths societal costs transformative medicines ● D
Slide 14: R&D Excellence: Our solutions
R&D Excellence: Our solutions We identified six solutions to achieve top quartile performance - with implementation ongoing Adopt a unified portfolio Transform our portfolio Access the best external framework management & governance innovation Introduce the ‘Bar’ to recognize assets Reconfigure end-
Slide 15: 'Fast-track' of selected programs
‘Fast-track’ of selected programs Initial set of assets designated for acceleration based on exceptional potential Asset Acceleration Examples of potential acceleration levers: anti-TL1A Expediting enrollment with additional clinical trial Ph III Inflammatory Bowel Disease1 sites Trontinemab Ph III
Slide 16: Embracing bold objectives: Our 2030 R&D ambitions
Embracing bold objectives: Our 2030 R&D ambitions Toward top quartile industry performance Increase average peak year sales of Increase Ph 0 initiations/yr1: Increase Ph III success rate: pipeline assets: +50% +22%p +50% Success Volume Value rate Effectiveness R&D Excellence Costs Cycle time Efficie
Slide 17: Meaningful improvements achieved in 2024
Meaningful improvements achieved in 2024 R&D Excellence enables us to reallocate resources to new projects, new deals & accelerate priority assets Added 5 assets trough high-value CHF +0.24bn average peak year sales per Recent team-assessed PTS for partnerships and 8 assets from project trough termi
Slide 18: Pharma pipeline evolution since Pharma Day 2023
Pharma pipeline evolution since Pharma Day 2023 Since Pharma Day 2023 17 NMEs were added and 26 NMEs removed, resulting in a higher impact portfolio Pipeline changes since Q2’23 siRNA targeting AGT in hypertension 8 -8 17 Additions 81 4 -3 1 • 8 Ph I/Ph II NMEs acquired as -5 3 -4 2 part of high val
Slide 19: Pipeline acceleration through partnering and acquisitions
Pipeline acceleration through partnering and acquisitions Key deals completed to complement our pipeline across the Pharma focus therapeutic areas *pending deal closure; CVRM=cardiovascular, renal & metabolism; siRNA=small interfering RNA; AGT=angiotensinogen; TL1A=Tumor necrosis factor-like cytokin
Slide 20: Leveraging AI to increase overall Pharma productivity
Data & AI Leveraging AI to increase overall Pharma productivity Selected AI use cases along the value chain Regulatory & Manufacturing Drug development Commercialization reimbursement & distribution gRED’s ‘Lab-in-a-loop’ Document writing Digital twin Predictive alerts • AI/ML: Computational • Gen A
Slide 21: Replay of Roche's Digitalization Day available on the IR homepage
Replay of Roche’s Digitalization Day available on the IR homepage CVM/EASD Pharma Day Neurology/CTAD Digitalization Day Sep 13 Sep 30 Oct 31 Nov 25 • Key data presented at EASD: • Group & Pharma strategy • Overview of the Roche • Roche digital efforts in Pharma • CT-388 (Ph I cohort 11 & 12 in updat
Slide 22: Lab in a loop in drug R&D
Lab in a loop in drug R&D Embedded in each component, from target discovery to the clinic 22
Slide 23: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 24: Peak sales potential of key pipeline assets (NMEs and LEs)
Peak sales potential of key pipeline assets (NMEs and LEs) New Molecular Entities (NME) giredestrant prasinezumab astegolimab HR+ BC Parkinson's disease COPD inavolisib fenebrutinib ASO Factor B • 7+ NMEs with CHF >3bn peak Pi3Km BC RMS, PPMS IgAN sales potential per asset divarasib Elevidys1 vamiki
Slide 25: 2025: Significant key newsflow ahead
2025: Significant key newsflow ahead* Compound Indication Milestone inavolisib + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC EU approval Columvi + GemOx 2L+ DLBCL US/EU approval Lunsumio SC 3L+ FL US/EU approval Elevidys DMD EU approval Gazyva Lupus nephritis US/EU filing; US approval Regulatory
Slide 26: Doing now what patients need next
Doing now what patients need next
Roche Holding — Bernstein's 23rd Annual Pan European Premium Review Conference 2024 on 6ix